Management of Functional Constipation
Start with polyethylene glycol (PEG) 17g daily as first-line pharmacological therapy for functional constipation, with bisacodyl or sodium picosulfate reserved for short-term use (≤4 weeks) or rescue therapy. 1
Stepwise Treatment Algorithm
First-Line: Osmotic Laxatives
Polyethylene glycol (PEG) receives a strong recommendation with moderate certainty evidence as the primary pharmacological agent 1. Start at 17g daily and titrate based on symptom response. PEG demonstrates durable efficacy over 6 months with common but manageable side effects including abdominal distension, loose stools, flatulence, and nausea 1.
- Before or alongside PEG: Consider fiber supplementation (14g/1,000 kcal daily intake) for mild constipation, though ensure adequate hydration as bloating and abdominal discomfort are common 1
- Alternative osmotic agents if PEG fails or is not tolerated:
Second-Line: Stimulant Laxatives
Bisacodyl (5mg daily, max 10mg) or sodium picosulfate receive strong recommendations with moderate certainty evidence, but specifically for short-term use (≤4 weeks) or as rescue therapy 1. While longer-term use is probably appropriate, data on tolerance and side effects with extended use remain limited. These agents work well as occasional rescue therapy combined with other agents 1.
Senna (8.6-17.2mg daily) receives a conditional recommendation with low certainty evidence 1. Start at lower doses than the trial-tested doses and increase as tolerated, as abdominal pain and cramping occur with higher doses. Though trials lasted only 4 weeks, longer-term use is probably appropriate 1.
Third-Line: Prescription Secretagogues
For patients who fail or are intolerant to over-the-counter therapies, consider:
Lubiprostone (conditional recommendation, low certainty evidence) can be used as replacement or adjunct to OTC agents 1. Trial durations ranged from 4-24 weeks with no label-specified limit. Side effects include headache, abdominal pain, nausea, and diarrhea 1.
The guidelines also mention other prescription agents including linaclotide and prucalopride, though specific recommendations are not fully detailed in the provided evidence 2, 3.
Critical Implementation Considerations
Common Pitfalls to Avoid
Renal function screening: Always assess renal function before prescribing magnesium oxide - hypermagnesemia risk is real and dangerous 1
Pregnancy considerations: Lactulose is the only osmotic agent specifically studied in pregnancy 1
Stimulant laxative misconceptions: Despite historical concerns, current evidence supports bisacodyl/picosulfate safety for short-term use with moderate certainty 1. However, prolonged or excessive use can cause diarrhea and electrolyte imbalance 1
Fiber supplementation timing: Ensure adequate hydration increases alongside fiber intake to prevent worsening symptoms 1
Cost considerations: PEG ($10-45/month), magnesium oxide, lactulose, bisacodyl, and senna all cost <$50/month, making them accessible first-line options 1
When to Escalate Beyond Basic Pharmacotherapy
Consider physiological testing (anorectal manometry, balloon expulsion test, defecography) for patients who:
- Fail to respond to available laxatives
- Are strongly suspected of having a defecatory disorder (pelvic floor dysfunction) 2, 3
For truly refractory cases after exhausting pharmacological options, consider biofeedback therapy for pelvic floor dysfunction, neuromodulation techniques, or in rare cases surgical interventions 4, 5.
Strength of Evidence Framework
The 2023 AGA-ACG guideline uses GRADE methodology 1:
- Strong recommendations (PEG, bisacodyl/picosulfate) mean most patients should receive the intervention
- Conditional recommendations (magnesium oxide, lactulose, senna, lubiprostone) require shared decision-making considering individual patient values and preferences
The evidence certainty ranges from moderate (PEG, stimulant laxatives) to very low (magnesium oxide, lactulose), reflecting the quality and consistency of available trials 1.